Ixoten therapy in malignant lymphomas
Pötzi, P.; Aiginger, P.; Kühböck, J.
Acta Medica Austriaca 6(5): 247-249
1979
ISSN/ISBN: 0303-8173 PMID: 400215 Document Number: 153759
Clinical experience with Ixoten (trofosfamide), a derivative of cyclophosphamide, is reported in 29 patients with malignant lymphomas. Daily doses of 150-300 mg p.o. and 6.000-200.000 mg total dose respectively, resulted in an 80% complete or partial remission. In addition to a dose dependent haematotoxicity, other side effects (gastrointestinal and/or hair loss) were almost negligible.